Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Diya Surie, Levi Bonnell, Katherine Adams, Manjusha Gaglani, Adit A. Ginde, David J. Douin, H. Keipp Talbot, Jonathan D. Casey, Nicholas M. Mohr, Anne Zepeski, Tresa McNeal, Shekhar Ghamande, Kevin W. Gibbs, D. Clark Files, David N. Hager, Arber Shehu, Anne P. Frosch, Heidi L. Erickson, Michelle N. Gong, Amira MohamedNicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Ithan D. Peltan, Samuel M. Brown, Emily T. Martin, Akram Khan, William S. Bender, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Carolina Rivas, Jennie H. Kwon, Matthew C. Exline, Adam S. Lauring, Nathan I. Shapiro, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Todd W. Rice, William B. Stubblefield, Adrienne Baughman, Kelsey N. Womack, Kimberly W. Hart, Sydney A. Swan, Yuwei Zhu, Jennifer DeCuir, Mark W. Tenforde, Manish M. Patel, Meredith L. McMorrow, Wesley H. Self

Research output: Contribution to journalArticlepeer-review

36 Scopus citations

Fingerprint

Dive into the research topics of 'Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences

Chemical Compounds